In the past decade (2012-2022), the pharmaceutical industry has become one of the most fast-growing sectors of the domestic industry of the Russian Federation. During this period, the production of domestic drugs in the domestic market was steadily increasing, including original drugs, and the independence from foreign suppliers was significantly strengthened.
Import substitution in action
Measures to ensure the drug safety of Russia were implemented in accordance with the Decree of the President of the Russian Federation No. 598 “On improving state policy in the field of healthcare” dated 07.05.2012. The goal was to increase the volume of domestic drug production to 90% as per the List of Strategically Important Drugs and the List of Vital and Essential Drugs. These priorities are also reflected in the Drug Supply Strategy of the Russian Federation for the period up to 2025 and in the Development Strategy of the Pharmaceutical Industry of Russia. The state program of the Russian Federation called “The Development of the Pharmaceutical and Medical Industry” has also begun to be implemented. The key objective of the program is to move the domestic market away from import dependence.
In 2016, the share of vital and essential drugs (VED) produced in the country reached 70%. By the end of 2022, this figure has increased to 82%, which has become a major achievement of modern-day Russia. Furthermore, currently 53% of drugs are produced according to the full production cycle.
The positive growth dynamics of the domestic pharma industry can be illustrated by the case of the FSUE Moscow Endocrine Plant. In 2014, Mikhail Yuryevich Fonarev was appointed as its director. Being an experienced manager and a Ph.D. in Law candidate, from his very first days, he focused on further developing of production, the introduction of new technologies, and the strengthening of the scientific base.
Comment type is not specified in the component properties.